140 related articles for article (PubMed ID: 6792)
1. Cholestyramine-induced inhibition of salicylazosulfapyridine (sulfasalazine) metabolism by rat intestinal microflora.
Pieniaszek HJ; Bates TR
J Pharmacol Exp Ther; 1976 Jul; 198(1):240-5. PubMed ID: 6792
[TBL] [Abstract][Full Text] [Related]
2. NTP Toxicology and Carcinogenesis Studies of Salicylazosulfapyridine (CAS No. 599-79-1) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1997 May; 457():1-327. PubMed ID: 12587019
[TBL] [Abstract][Full Text] [Related]
3. The role of intestinal bacteria in the metabolism of salicylazosulfapyridine.
Peppercorn MA; Goldman P
J Pharmacol Exp Ther; 1972 Jun; 181(3):555-62. PubMed ID: 4402374
[No Abstract] [Full Text] [Related]
4. Distribution studies of salicylazosulfapyridine and its metabolites.
Peppercorn MA; Goldman P
Gastroenterology; 1973 Feb; 64(2):240-5. PubMed ID: 4405598
[No Abstract] [Full Text] [Related]
5. Colonic azodisalicylate metabolism determined by in vivo dialysis in healthy volunteers and patients with ulcerative colitis.
Lauritsen K; Hansen J; Ryde M; Rask-Madsen J
Gastroenterology; 1984 Jun; 86(6):1496-500. PubMed ID: 6143704
[TBL] [Abstract][Full Text] [Related]
6. Steady-state kinetics of 5-aminosalicylic acid and sulfapyridine during sulfasalazine prophylaxis in ulcerative colitis.
Bondesen S; Nielsen OH; Schou JB; Jensen PH; Lassen LB; Binder V; Krasilnikoff PA; Danø P; Hansen SH; Rasmussen SN
Scand J Gastroenterol; 1986 Aug; 21(6):693-700. PubMed ID: 2875518
[TBL] [Abstract][Full Text] [Related]
7. Susceptibility of Desulfovibrio desulfuricans intestinal strains to sulfasalazine and its biotransformation products.
Dzierzewicz Z; Cwalina B; Weglarz L; Wiśniowska B; Szczerba J
Med Sci Monit; 2004 Jun; 10(6):BR185-90. PubMed ID: 15173665
[TBL] [Abstract][Full Text] [Related]
8. [Comparison of salicylazosulfapyridine bioavailability following oral and rectal administration in patients with ulcerative colitis].
Sliwiński Z
Pol Tyg Lek; 1991 Nov 11-25; 46(45-47):879-81. PubMed ID: 1688291
[TBL] [Abstract][Full Text] [Related]
9. [Ulcerative colitis in children. Levels of salicylazosulfapyridine and sulfapyridine during treatment].
Guastavino E; Litwin NH; Heffes Nahmod L; Licastro R
Acta Gastroenterol Latinoam; 1988; 18(2):107-13. PubMed ID: 2908013
[TBL] [Abstract][Full Text] [Related]
10. Role of the intestinal flora in the acetylation of sulfasalazine metabolites.
Dull BJ; Salata K; Goldman P
Biochem Pharmacol; 1987 Nov; 36(21):3772-4. PubMed ID: 2890356
[No Abstract] [Full Text] [Related]
11. Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin.
Chungi VS; Dittert LW; Shargel L
Pharm Res; 1989 Dec; 6(12):1067-72. PubMed ID: 2576130
[TBL] [Abstract][Full Text] [Related]
12. Determination of the active moiety of BX661A, a new therapeutic agent for ulcerative colitis, by studying its therapeutic effects on ulcerative colitis induced by dextran sulfate sodium in rats.
Kimura I; Kawasaki M; Nagahama S; Matsuda A; Kataoka M; Kokuba Y
Arzneimittelforschung; 1998 Nov; 48(11):1091-6. PubMed ID: 9850431
[TBL] [Abstract][Full Text] [Related]
13. Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.
Yamaguchi T; Sasaki K; Kurosaki Y; Nakayama T; Kimura T
J Drug Target; 1994; 2(2):123-31. PubMed ID: 7915179
[TBL] [Abstract][Full Text] [Related]
14. Absorption, metabolism, and excretion of salicylazosulfapyridine in man.
Schröder H; Campbell DE
Clin Pharmacol Ther; 1972; 13(4):539-51. PubMed ID: 4402886
[No Abstract] [Full Text] [Related]
15. Disposition of salicylazosulfapyridine (Azulfidine) and metabolites in human breast milk.
Berlin CM; Yaffe SJ
Dev Pharmacol Ther; 1980; 1(1):31-9. PubMed ID: 6108198
[TBL] [Abstract][Full Text] [Related]
16. Disposition of disodium azodisalicylate in healthy subjects. A possible new drug for inflammatory bowel disease.
van Hogezand RA; van Hees PA; Zwanenburg B; van Rossum JM; van Tongeren JH
Gastroenterology; 1985 Mar; 88(3):717-22. PubMed ID: 2857146
[TBL] [Abstract][Full Text] [Related]
17. In virto adsorption of bile salts to food residues, salicylazosulfapyridine, and hemicellulose.
Birkner HJ; Kern F
Gastroenterology; 1974 Aug; 67(2):237-44. PubMed ID: 4152619
[No Abstract] [Full Text] [Related]
18. Time course of free and N4-acetylated sulfapyridine concentrations in the plasma and saliva of man after sulfasalazine (salicylazosulfapyridine) administration: preliminary findings.
Bates TR; Blumenthal HP; Pieniaszek HJ
Res Commun Chem Pathol Pharmacol; 1976 Sep; 15(1):183-9. PubMed ID: 9675
[TBL] [Abstract][Full Text] [Related]
19. Role of prostaglandins in ulcerative colitis. Enhanced production during active disease and inhibition by sulfasalazine.
Sharon P; Ligumsky M; Rachmilewitz D; Zor U
Gastroenterology; 1978 Oct; 75(4):638-40. PubMed ID: 30669
[TBL] [Abstract][Full Text] [Related]
20. Colorimetric determination of 5-aminosalicylic acid and its N-acetylated metabolite on urine and feces.
Pieniaszek HJ; BatesTR
Res Commun Chem Pathol Pharmacol; 1975 Nov; 12(3):571-81. PubMed ID: 747
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
